Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity
Australasian Journal of Dermatology · 2024
DOI: 10.1111/ajd.14343 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von James Pham und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Adalimumab, Asian People, Hidradenitis Suppurativa, White People. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objectives Caucasian and Asian patients with hidradenitis suppurativa demonstrate significant differences with regard to age, gender and body mass index. Demographic characteristics are known to influence the efficacy and drug survival of hidradenitis suppurativa therapeutics including biologic therapies. What remains unknown is the impact of ethnicity upon the efficacy of therapeutics once demographic and disease characteristics have been taken into account. This is an important question given the expansion of biologic therapies for HS into the global patient community.
Methods
We assessed 170 patients from a single HS specialist centre in Australia stratified by patient‐identified ethnicity including those identifying as either Caucasian or Asian.
Results
Asian patients demonstrated lower BMI, higher rates of smoking and greater odds of Hurley stage 3 disease with tunnels than Caucasian patients in line with the reported literature. There was no significant difference between percentage of individuals achieving HiSCR50 or IHS4‐55 at Week 16. Significant differences were seen in median time to secondary loss of response, and Kaplan–Meier curve analysis showed a significant difference between curves when stratified by patient‐reported ethnicity. Cox regression analysis demonstrated after accounting for age, gender, BMI, smoking and Hurley stage, the significance of ethnicity in influencing time to secondary loss of response disappears.
Conclusions
Caucasian or Asian ethnicity does not influence response to adalimumab treatment on patients with hidradenitis suppurativa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, Australia.
- Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia.
- School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
- Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore.
- The Skin Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Akshay Flora
Zitieren
APA
Pham, J., Flora, A., Guttman, L., Allan, T., Chandran, N. S., & Frew, J. W. (2024). Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14343
Vancouver
Pham J, Flora A, Guttman L, Allan T, Chandran NS, Frew JW. Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14343
BibTeX
@article{Pham2024,
author = {Pham, James and Flora, Akshay and Guttman, Lauren and Allan, Timothy and Chandran, Nisha Suyien and Frew, John W},
title = {Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient‐reported ethnicity},
journal = {Australasian Journal of Dermatology},
year = {2024},
doi = {10.1111/ajd.14343}
}
EUVIMED